Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.2100
-0.0001 (-0.05%)
At close: Jul 31, 2026, 4:00 PM EDT
0.2131
+0.0031 (1.48%)
After-hours: Jul 31, 2026, 8:00 PM EDT
Theriva Biologics Employees
As of December 31, 2025, Theriva Biologics had 16 total employees, including 15 full-time and 1 part-time employees. The number of employees decreased by 6 or -27.27% compared to the previous year.
Employees
16
Change (1Y)
-6
Growth (1Y)
-27.27%
Revenue / Employee
$18,750
Profits / Employee
-$1,435,563
Market Cap
9.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | -6 | -27.27% | 15 | 1 |
| Dec 31, 2024 | 22 | 0 | - | 20 | 2 |
| Dec 31, 2023 | 22 | 1 | 4.76% | 22 | 0 |
| Dec 31, 2022 | 21 | 5 | 31.25% | 21 | 0 |
| Dec 31, 2021 | 16 | 6 | 60.00% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 41 |
| Senti Biosciences Holdings | 39 |
| Lunai Bioworks | 29 |
| Curis | 24 |
| BioCardia | 21 |
| Lisata Therapeutics | 21 |
| IN8bio | 18 |
| Lexaria Bioscience | 7 |
TOVX News
- 25 days ago - Theriva Biologics gets regulatory authorization to proceed with VIRAGE2 in Spain - TheFly
- 25 days ago - Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 4 weeks ago - Theriva Biologics Proxy statement: Proxy filing - Filings
- 6 weeks ago - Theriva Biologics Proxy statement: Proxy filing - Filings
- 7 weeks ago - Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research - GlobeNewsWire
- 2 months ago - Theriva Biologics Slides: Corporate presentation - Filings
- 3 months ago - Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - GlobeNewsWire
- 3 months ago - Theriva Biologics Earnings release: Q1 2026 - Filings